Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on November 9, 2022. The report addresses a deficiency in the Company's stock listing status on the Nasdaq Stock Market due to the common stock's bid price closing below the $1.00 minimum requirement for 30 consecutive business days.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
- Listing Transfer: Nasdaq approved the transfer of Akebia's common stock from the Nasdaq Global Market to the Nasdaq Capital Market, effective November 11, 2022.
- Compliance Extension: The Company was granted an additional 180-day compliance period (until May 8, 2023) to regain compliance with the $1.00 minimum bid price requirement.
- Trading Symbol: The stock will continue to trade under the symbol "AKBA."
Outlook, Risks, and Management Commentary
Management intends to cure the deficiency during the extended compliance period, potentially by effecting a reverse stock split. The Company must maintain a closing bid price of $1.00 or more for 10 consecutive business days to regain full compliance. If the Company fails to meet this requirement by May 8, 2023, Nasdaq will notify the Company of delisting. The Company may appeal such a determination to a Nasdaq Listing Qualifications Panel, though there is no assurance of success. Pending any appeal, the stock is expected to remain listed on the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the effective date of the transfer to the Nasdaq Capital Market (November 11, 2022).
- Monitor the daily closing bid price to track progress toward the 10-day compliance window.
- Watch for announcements regarding a potential reverse stock split to address the bid price deficiency.
- Note the final deadline for compliance (May 8, 2023) to avoid potential delisting.